Comparison of itraconazole and ketoconazole in HIV-Positive patients with oropharyngeal or esophageal candidiasis

Chemotherapy

Volumn 42, Issue 5, 1996, Pages 374-383

  de Repentigny, Louis ^a,b   Ratelle, Johanne ^a,b   Baril, Jean Guy ^c   Frechette, Gervais ^c   Tsoukas, Christos ^d   Lemicux, Claude ^e   Vincelette, Jean ^f   Lalonde, Richard ^g   René, Pierre ^g   Phaneuf, Denis ^h   Côté, Pierre ⁱ   Dascal, André ^j   Auger, Pierre ^k   Cholette, Pierre ^l   StGermain, Guy ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^c Clinique Mont Carmel   (Canada)

^d MONTREAL GENERAL HOSPITAL   (Canada)

^e NOTRE DAME HOSPITAL   (Canada)

^f Hôpital Saint Lue   (Canada)

^g ROYAL VICTORIA HOSPITAL   (Canada)

^h CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ Clinique de l Alternative   (Canada)

^j MCGILL UNIVERSITY   (Canada)

^k Hôpital Fleury   (Canada)

^l Clinique Médicale 1851   (Canada)

more..

Author keywords

Candidiasis; Esophagitis; HIV; Itraconazole; Ketoconazole; Oral thrush

Indexed keywords

ANTIFUNGAL AGENT; ITRACONAZOLE; KETOCONAZOLE;

ARTICLE; ASTHENIA; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; ESOPHAGUS DISEASE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; OROPHARYNX; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE RISK; TASTE DISORDER; TREATMENT OUTCOME; VOMITING;

EID: 0029836413     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000239469     Document Type: Article

References (17)

1. Grant SM, Clissold SP: Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties. and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310-344.
2. Blatchford NR: Treatment of oral candidosis with itraconazole: A review. J Am Acad Dermatol 1990:23: 565-567.
3. Chiang CL: The Lifetable and Its Applications. Malabar. Krieger Publishing. 1984.
4. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wklv Rep 1992;41:1-19.
5. De Wit S, Goossens H, Weerts D, Clumeck N: Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989;i:746-748.
6. Laine L, Dretler RH, Corneas CN. Tuazon C, Koster FM. Sattler F. Squires K, Islam MZ: Fluconazole compared w ith ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann Intern Med 1992;117:655-660.
7. Hay RJ: Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis 1990:12:S334-S337.
8. Leen CLS, Dunbar EM, Ellis ME, Mandal BK: Oncc-wcckly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: A double-blind placebo-controlled study. J Infect 1990:21:55-60.
9. Stevens DA, Greene SI, Lang OS: Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired mini u no-deficiency syndrome-related complex. Randomized, doubleblind, placebo-controlled study of 100 mg oral fluconazole daily. Arch Intern Med 1991:151:2458-2464.
10. Marriott DJE, Jones PD, Hoy JF, Speed BR, Harkness JL: Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. Med J Aust 1993:158:312-316.
11. Akova M, Akalin HE, Uzun O, Gttr D: Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis 1991:10:598-599.
12. Sanguineti A, Carmichael K, Campbell K: Fluconazole-resistant Candida albicans after long-term suppressive therapy. Arch Intern Med 1993; 153:1122-1124.
13. Smith D, Boag F, Midglcy J, Gaz-zard B: Fluconazole resistant Candida in AIDS (letters to the editor). J Infect 1991:23:345-346.
14. Bart-Dclabesse E, Boiron P, Carlotti A, Dupont B: Candida albicans ge-notyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol 1993: 31:2933-2937.
15. Just G, Steinheimer D, Schnellbach M, Böttingcr C, Helm EB, Stille W: Change of causative organisms under antifunga! treatment in immu-nosuppresscd patients with HIV-in-fections. Mycoses 1989:32:47-51.
16. Smith DE, Midgley J, Allan M, Connolly GM, Gazzard BG: Itraconazole versus ketoconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV. AIDS 1991:5:1367-1371.
17. Sl-Germain G, Dion C, Espinel-In-grof TA. Ratelle J, de Repcnligny L: Ketoconazole and itraconazole susceptibility of Candida albicans isolated from patients infected with HIV. J Antimicrob Chemother 1995;36:109-118.